- Safety Confirmed with No Concerns Reported in Cohort 1 - - Approval to Immediately Proceed to Cohort 2 - ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Jun. 13, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX) and Cell Cure Neurosciences Ltd. (Cell Cure), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell ...
[Continue Reading]

- Israel Innovation Authority awards a grant to Cell Cure Neurosciences, a BioTime Subsidiary, that will supportongoing development of OpRegen®, to address a leading cause of blindness, dry-AMD - This is the 10th year in receipt of an Israeli Government grant in support of Cell Cure ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Jun. 10, ...
[Continue Reading]

ALAMEDA, CA and JERUSALEM, Israel--Sept. 28, 2015--BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for OpRegen®, a cell-based therapeutic product consisting of retinal pigment epithelial (RPE) ...
[Continue Reading]

Data to be Presented at Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting  ALAMEDA, Calif. and JERUSALEM, Israel, May 4, 2015 – BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that preclinical data demonstrating that Cell Cure’s product candidate, ...
[Continue Reading]

ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–Feb. 17, 2015– BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) today provided an update on Cell Cure’s product development and partnering activities. On February 16, 2015, Cell Cure opened the clinical trial of OpRegen® titled “Phase I/IIa Dose ...
[Continue Reading]

• IND cleared for Phase I/IIa dose escalation trial in patients with the dry form of age-related macular degeneration (AMD) called geographic atrophy (GA) • No approved therapy exists for dry-AMD, the leading cause of visual impairment in an aging population in the US and other developed countries • OpRegen® will be the first preparation of ...
[Continue Reading]

IND filed for a Phase I/IIa dose escalation trial in patients with dry-AMD No approved therapy exists for dry-AMD, the leading cause of visual impairment in the aging population OpRegen® will be the first preparation of xeno-free RPE cells to be evaluated clinically for dry-AMD ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Oct. 6, 2014-- ...
[Continue Reading]

ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Sep. 17, 2014-- BioTime, Inc. (NYSE MKT and TASE: BTX), HBL Hadasit Bio-Holdings Ltd. (Tel Aviv Stock Exchange: HDST) and Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has received the final results of a series of extensive preclinical safety and efficacy studies of its ...
[Continue Reading]

ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Dec. 23, 2013-- BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2014 of 6.1 million Shekels (approximately $1.74 million) from Israel’s Office of the Chief Scientist (OCS) to help finance ...
[Continue Reading]

ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Aug. 1, 2012-- BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2012 of 5.04 million Shekels (approximately $1.33 million) from Israel’s Office of the Chief Scientist (OCS) to help finance ...
[Continue Reading]